Build with KISHO Sign In Sign Up

Kisho

Deciphera Pharmaceuticals, LLC — Rare Disease Pipeline | Kisho | Kisho

Deciphera Pharmaceuticals, LLC

Other

5

Orphan Designations

2

FDA Approvals

14

Rare Diseases

0

News Articles

Disease	Drug(s)	Designation	Approved
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)	Rebastinib	Orphan Designation	-
Carney-Stratakis syndrome	Ripretinib	Orphan Designation	-
IDH-mutant anaplastic astrocytoma	KIT and PDGFR inhibitor	Orphan Designation	-
IDH-wildtype anaplastic astrocytoma	KIT and PDGFR inhibitor	Orphan Designation	-
Philadelphia-positive myelogenous leukemia	Rebastinib	Orphan Designation	-
adult-onset non-insulinoma persistent hyperinsulinemic hypoglycemia	Ripretinib	Orphan Designation	-
anaplastic astrocytoma	KIT and PDGFR inhibitor	Orphan Designation	-
chronic myelogenous leukemia, BCR-ABL1 positive	Rebastinib	Orphan Designation	-
colorectal gastrointestinal stromal tumor	Ripretinib	Orphan Designation	-
gastrointestinal stromal tumor	Ripretinib	Orphan Designation	-
glioma susceptibility 1	KIT and PDGFR inhibitoraltiratinib	Orphan Designation	-
pheochromocytoma/paraganglioma syndrome 4	Ripretinib	Orphan Designation	-
primary adult heart tumor	Ripretinib	Orphan Designation	-
primary central nervous system lymphoma	tirabrutinib	Orphan Designation	-

← Back to Companies